- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterNCI CANCERLIT® Search: Wilms' Tumor - July 2002
National Cancer Institute®
Last Modified: July 1, 2002
- Sudden death due to undiagnosed Wilms' tumor in an adult.
- Use of chest computed tomography for staging and treatment of Wilms' tumor in children.
- Role of chest computed tomography at diagnosis in the management of Wilms' tumor: a study by the United Kingdom Children's Cancer Study
- Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition.
- Nephroblastoma. DNA characteristics and their modifications induced by prenephrectomy chemotherapy: a cytofluorimetric study.
- Morbid obesity and hyperphagia in the WAGR syndrome.
- Somatic glypican 3 (GPC3) mutations in Wilms' tumour.
- Recent progress in the biology and treatment of Wilms' tumor.
- Papillonodular type of cystic partially differentiated nephroblastoma: a case report.
- Wilms' tumor (nephroblastoma).
- [Radiotherapy in multiple modality treatment of children with nephroblastoma]
- [Wilms tumor in adults. Report of a case]
- Simultaneous occurrence of Wilms tumor and rhabdomyosarcoma in two patients.
- Wilms tumor: progress to date and future considerations.
Table of Contents
1
UI - 12051352
AU - Oeberst JL; Barnard JJ; Prahlow JA
TI -
Sudden death due to undiagnosed Wilms' tumor in an adult.
SO - J Forensic Sci 2002 May;47(3):638-9
AD - Southwestern Institute of Forensic Sciences and University of Texas
Southwestern Medical School, Department of Pathology, Dallas, USA.
Sudden unexpected deaths due to natural causes constitute a large number
of cases encountered by the forensic pathologist. In a majority of such
cases, heart disease is responsible for sudden death. Rare disease
entities resulting in sudden death are occasionally encountered and may
not fit the classic epidemiological profile. We present a case of sudden
death due to a previously undiagnosed Wilms' tumor (WT) in an adult. The
pathology of WT is discussed, as is the topic of sudden death due to
previously unrecognized malignancy.
2
UI - 12065550
AU - Green DM
TI -
Use of chest computed tomography for staging and treatment of Wilms'
tumor in children.
SO - J Clin Oncol 2002 Jun 15;20(12):2763-4
3
UI - 12065552
AU - Owens CM; Veys PA; Pritchard J; Levitt G; Imeson J; Dicks-Mireaux C
TI -
Role of chest computed tomography at diagnosis in the management of
Wilms' tumor: a study by the United Kingdom Children's Cancer Study
Group.
SO - J Clin Oncol 2002 Jun 15;20(12):2768-73
AD - Department of Radiology, Great Ormond Street Hospital for Children
National Health Service Trust, London, United Kingdom.
PURPOSE: This study sought to determine whether the identification of
minimal pulmonary metastatic disease by chest computed tomography (CT)
performed at diagnosis in patients with Wilms' tumor and normal chest
x-rays (CXR) could predict a subgroup of children at increased risk of
pulmonary relapse. PATIENTS AND METHODS: A retrospective analysis was
carried out of the records of 449 children entered onto the United
Kingdom Childrens' Cancer Study Group Second Wilms' Tumor Study between
chest CT at diagnosis, but 141 children who had normal frontal and
lateral CXRs and a chest CT scan performed at diagnosis were eligible
for analysis. After surgery, children with stage I Wilms' tumor received
single-agent chemotherapy (vincristine), whereas children with stages
II, III, and bilateral Wilms' tumor received combination chemotherapy.
Most children with stage III tumors were also treated with abdominal
radiotherapy (20 Gy). RESULTS: In 31 patients (22%), pulmonary nodules
were visible on chest CT; eight experienced relapse, four (15%) in the
lungs. When only stage I patients were analyzed, there was a significant
difference between the pulmonary relapse rate of 43% (three of seven) in
the CT-positive group and 10% (five of 48) in the CT-negative group (P
=.02). Four of eight patients with stage I disease with pulmonary
relapse died. CONCLUSION: CT seemed to identify a subgroup of stage I
patients who were at increased risk of pulmonary relapse. These children
had received only single-agent chemotherapy. A prospective randomized
trial is needed to clarify whether these children would benefit from
combination chemotherapy.
4
UI - 12057921
AU - Li CM; Guo M; Borczuk A; Powell CA; Wei M; Thaker HM; Friedman R; Klein
TI -
U; Tycko B
Gene expression in Wilms' tumor mimics the earliest committed stage in
the metanephric mesenchymal-epithelial transition.
SO - Am J Pathol 2002 Jun;160(6):2181-90
AD - Institute for Cancer Genetics, Columbia University, New York, New York,
USA.
Wilms' tumor (WT) has been considered a prototype for arrested cellular
differentiation in cancer, but previous studies have relied on selected
markers. We have now performed an unbiased survey of gene expression in
WTs using oligonucleotide microarrays. Statistical criteria identified
357 genes as differentially expressed between WTs and fetal kidneys.
This set contained 124 matches to genes on a microarray used by Stuart
and colleagues (Stuart RO, Bush KT, Nigam SK: Changes in global gene
expression patterns during development and maturation of the rat kidney.
Proc Natl Acad Sci USA 2001, 98:5649-5654) to establish genes with
stage-specific expression in the developing rat kidney. Mapping between
the two data sets showed that WTs systematically overexpressed genes
corresponding to the earliest stage of metanephric development, and
underexpressed genes corresponding to later stages. Automated clustering
identified a smaller group of 27 genes that were highly expressed in WTs
compared to fetal kidney and heterologous tumor and normal tissues. This
signature set was enriched in genes encoding transcription factors. Four
of these, PAX2, EYA1, HBF2, and HOXA11, are essential for cell survival
and proliferation in early metanephric development, whereas others,
including SIX1, MOX1, and SALL2, are predicted to act at this stage.
SIX1 and SALL2 proteins were expressed in the condensing mesenchyme in
normal human fetal kidneys, but were absent (SIX1) or reduced (SALL2) in
cells at other developmental stages. These data imply that the blastema
in WTs has progressed to the committed stage in the
mesenchymal-epithelial transition, where it is partially arrested in
differentiation. The WT-signature set also contained the Wnt receptor
FZD7, the tumor antigen PRAME, the imprinted gene NNAT and the
metastasis-associated transcription factor E1AF.
5
UI - 11842975
AU - Camassei FD; Ferlini C; Jenkner A; Bosman C; Biselli R; Donfrancesco A;
TI -
Boldrini R
Nephroblastoma. DNA characteristics and their modifications induced by
prenephrectomy chemotherapy: a cytofluorimetric study.
SO - Pediatr Pathol Mol Med 2002 Jan-Feb;21(1):15-23
AD - Department of Pathology, Bambino Gesu Children's Hospital-Research
Institute, Rome, Italy.
Treatment of nephroblastoma (Wilms' tumor) has presently achieved a 90%
survival rate. Stage and grade are considered the most reliable
prognostic parameters, but other biological factors are under study in
order to improve patient stratification. Deoxyribonucleic acid (DNA)
ploidy has been suggested to be useful in this setting. We
retrospectively studied 79 patient with nephroblastoma (58 pretreated
with chemotherapy and 21 not pretreated) by means of flow cytometry. DNA
content and synthetic phase values were correlated with pathologic
features and outcome. DNA modifications induced by chemotherapy were
investigated. Sixty-nine tumors were diploid and 10 aneuploid. DNA
content did not correlate with clinical course and was not modified by
pretreatment. Aneuploid tumors were restricted to lower stages. Mean
S-phase rate was lower and did not vary according to histology in
pretreated tumors, while it was higher and increased with grade (p =
0.007) in previously untreated tumors. The fraction of cells in
synthetic activity was related to outcome: Patients whose tumors
displayed higher S-phase rates had a more favorable clinical course.
Ploidy did not appear to be of prognostic significance. S-phase rate
decreased after chemotherapy (p = 0.0002) and was related to survival.
The worse outcome of pretreated patients might be attributed to a minor
sensitivity to postoperative treatment: Preoperative chemotherapy would
decrease the cell proliferation and might select resistant cellular
clones of (possible) neoplastic residues.
6
UI - 11822711
AU - Amor DJ
TI -
Morbid obesity and hyperphagia in the WAGR syndrome.
SO - Clin Dysmorphol 2002 Jan;11(1):73-4
A 33-year-old man with WAGR syndrome is described with morbid obesity
associated with hyperphagia and an apparent lack of satiety. It is
possible that a gene associated with satiety is present at 11p13
although it is premature to conclude that obesity is a specific feature
of WAGR syndrome.
7
UI - 12085187
AU - White GR; Kelsey AM; Varley JM; Birch JM
TI -
Somatic glypican 3 (GPC3) mutations in Wilms' tumour.
SO - Br J Cancer 2002 Jun 17;86(12):1920-2
AD - Cancer Research UK Cancer Genetics Group, Paterson Institute for Cancer
Research, Wilmslow Road, Manchester M20 4BX, UK.
Tumour and normal tissue from 41 male cases of Wilms' tumour were
screened to determine the presence of sequence variants in the glypican
3 (GPC3) gene. Two non-conservative single base changes were present in
tumour tissue only. These findings imply a possible role for GPC3 in
Wilms' tumour development. Copyright 2002 Cancer Research UK
8
UI - 12084281
AU - Ritchey ML
TI -
Recent progress in the biology and treatment of Wilms' tumor.
SO - Curr Urol Rep 2001 Apr;2(2):127-31
AD - Division of Urology, University of Texas-Houston Medical, 6431 Fannin,
6.018, Houston, TX 77030, USA. mritchey@utsurg.med.uth.tmc.edu
The survival rate of patients with Wilms' tumor has rapidly improved in
the last few decades. As we enter into the new millennium, overall
survival for all Wilms' tumor patients exceeds 80%. Two large
cooperative groups prospectively studied children with nephroblastoma:
the National Wilms' Tumor Study Group, and the International Society of
Paediatric Oncology. This review details the recent progress in
understanding the biology of Wilms' tumor. Advances in clinical
management of children with nephroblastoma are also outlined.
9
UI - 11837583
AU - Shiraishi A; Kuwatsuru R; Kurosaki Y; Maehara T; Fujita H; Miyano T;
TI -
Matsumoto T
Papillonodular type of cystic partially differentiated nephroblastoma: a
case report.
SO - Radiat Med 2001 Nov-Dec;19(6):313-6
AD - Department of Radiology, Juntendo University School of Medicine, Tokyo,
Japan.
We report a case of the papillonodular type of cystic partially
differentiated nephroblastoma (CPDN), an extremely rare renal neoplasm
that occurs in newborns and infants. The papillonodular type of CPDN is
a variant of the conventional form of CPDN. MRI clearly demonstrated the
gross pathologic features, distinguishing it from other renal
multilocular cystic tumors.
10
UI - 11734691
AU - McLorie GA
TI -
Wilms' tumor (nephroblastoma).
SO - Curr Opin Urol 2001 Nov;11(6):567-70
AD - Division of Urology, University of Toronto, and Hospital for Sick
Children, Toronto, Ontario, Canada. gmclorie@sickkids.on.ca
Wilms' tumor (nephroblastoma) is a subject which continues to challenge
clinicians in their attempts to achieve the best survival of their
patients, while minimizing morbidity. Overall survival of over 85% of
all children can now be achieved using combination therapy with
chemotherapy, surgery, and in some cases radiotherapy. Recent reviews of
two multi-institutional, multinational trials (the International Society
of Pediatric Oncology and the National Wilms' Tumor Study Group) are
discussed in this article, in which their current approaches to therapy
are presented. In addition to these clinical advances, the genetic and
molecular features of Wilms' tumor continue to provide insight into the
biology of nephroblastoma and into neoplasia in general. A recent review
of these aspects of the field is provided.
11
UI - 11882978
AU - Glekov IV; Lebedev VI; Belova VP; Dzhabarov FR; Danilova VS; Boichenko
TI -
EI; Sharoev TA
[Radiotherapy in multiple modality treatment of children with
nephroblastoma]
SO - Vestn Ross Akad Med Nauk 2002;(1):68-71
The role of radiotherapy in multiple modality treatment of Wilms' tumor
is evaluated in 225 children aged 3 months to 11.5 years (mean age 3.5
years) with stage III-IV. 184 (81.8%) patients presented with stage III,
93.7% with typical nephroblastoma. Intervention was combined with drug
and radiotherapy in 99.6% patients. Exposure of the abdominal cavity in
total focal doses of 10.5-50.2 Gy (mean dose 28 Gy) was carried out in
219 (97.3%) of 225 patients. Special attention is paid to the incidence
of relapses, remote metastases, and survival of patients in relation to
prognostic factors (sex, age, stage of tumor process, terms of exposure,
and total focal doses). All patients were followed up for 2-203 months
(median 32 months). During this period relapses and/or metastases were
observed in 34.2% patients; 30.2% died because of disease progress.
35.1% children live without signs of disease for more than 5 years,
14.7% for more than 10 years. Relapses were more incident during the
first year of treatment (in 65% children) and outside the exposed field
(72.5% cases). 33.2% patients with stage III developed metastases after
1-49 months; the lungs were involved most often. Prolongation of the
period between surgery and exposure of the abdominal cavity led to
increase in the incidence of relapses in the abdominal cavity from 6.7%
(up to 2 weeks) to 21.9% (more than 1 month), p = 0.02. Relapses were
the most frequent in children aged over 4 years. This parameter
virtually did not depend on the total focal dose. The absence of
relationship between the incidence of local relapses and life span after
exposure to a total focal dose of up to 21.6 Gy in comparison with
higher doses recommends reduced doses for therapy without notable
deterioration of the survival of patients with nephroblastoma.
12
UI - 11803784
AU - Carmona Campos E; Zarate Rodriguez E
TI -
[Wilms tumor in adults. Report of a case]
SO - Actas Urol Esp 2001 Nov-Dec;25(10):755-8
AD - Unidad de Urologia, Hospital Alto Guadalquivir, Andujar, Jaen.
OBJECTIVE: Wilms' tumor or nephroblastoma is the most common renal tumor
of childhood. The incidence in adults is rare, estimated at about 1% of
all cases and approximately 200 cases have been described in the world
literature. We report a new case of adult Wilms' tumor and realize a
short review. METHODS/RESULTS: We describe a case of Wilms' tumor in a
young male, aged 15 years, with associate genitourinary abnormalities.
The patient underwent radical nepherctomy with postoperative
chemotherapy. CONCLUSIONS: The Wilms' tumor in the adult population is
exceptional, and the definitive diagnostic is based in the findings of
the pathological analysis. The application of therapeutic protocolos for
children to adults offers an smaller percentage of cure and poorer
prognostic. Therapheutic protocolos more aggressive are necessary for
increase the worse prognostic in the adult, but because of the rarity is
difficult to define the most effective form of treatment.
13
UI - 12116068
AU - Muwakkit S; Antillon F; Valverde P; Jenkins JJ 3rd; Zaatari G; Dome JS
TI -
Simultaneous occurrence of Wilms tumor and rhabdomyosarcoma in two
patients.
SO - Med Pediatr Oncol 2002 Aug;39(2):143-5
14
UI - 12113088
AU - Ehrlich PF
TI -
Wilms tumor: progress to date and future considerations.
SO - Expert Rev Anticancer Ther 2001 Dec;1(4):555-64
AD - West Virginia University School of Medicine, Morgantown, WV, USA.
pehrlich@hsc.wvu.edu
Wilms tumor is the most common tumor of renal origin found in children.
In the last 50 years, remarkable progress has been made in the treatment
and understanding of children with Wilms tumor. Through the development
of multiagent chemotherapy and cooperative pediatric interdisciplinary
groups conducting large randomized controlled clinical trials, survival
has improved dramatically. In the next century it is expected that 80%
of children with Wilms tumor will be long-term survivors. Therapy is
progressing towards a risk-based management based not only on stage and
histology but also incorporated genetic markers. This article reviews
progress to date and possible future directions in the treatment of
Wilms Tumor.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
